Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.75
Bid: 31.50
Ask: 32.00
Change: -0.25 (-0.78%)
Spread: 0.50 (1.587%)
Open: 31.75
High: 31.75
Low: 31.75
Prev. Close: 32.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Successful Exit of Investment in Royalty Partner

14 Sep 2020 07:00

RNS Number : 8181Y
Duke Royalty Limited
14 September 2020
 

14 September 2020

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

 

Successful Exit of Investment in Royalty Partner 

 

Duke Royalty Limited (AIM: DUKE), a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, is pleased to announce the successful exit of its £2.0 million investment in Royalty Partner Xtremepush Limited ("Xtremepush"), the Dublin-based B2B technology platform. 

 

Highlights:

 

· The transaction represents Duke Royalty's first exit, further validating its funding model

· Post exit fees, the investment's IRR is in excess of 22%, with a cash-on-cash return in excess of 1.5x

· Duke retains its warrant over 3% of Xtremepush's share capital, representing further potential upside in the future

 

Xtremepush has been a Royalty Partner since February 2018. Operating in an online sector which has attracted substantial amounts of capital, Xtremepush has grown robustly in recent years through a combination of organic growth and M&A.  Duke's capital has played an important role in this, having been used to fund the strategic acquisitions of Emailcenter UK Limited ("Emailcenter") in March 2018 and Alchemetrics Limited ("Alchemetrics") in December 2019.  

 

Whilst Xtremepush represented one of the smaller investments within the Duke portfolio (£2.0 million), the deal has nonetheless returned an attractive IRR in excess of 22% to date, which is anticipated to be further enhanced following the eventual exercise of Duke's warrants over 3% of Xtremepush's share capital.

 

Neil Johnson, CEO of Duke Royalty, said:

 

"We have enjoyed working with the Xtremepush team as they have grown the business from strength to strength. We are proud of the role Duke's flexible capital solution has played in Xtremepush's recent success and wish Tommy and the team all the best as they continue to drive the business forward.

 

"We are equally pleased to have successfully generated returns in excess of 22% for Duke's shareholders, further validating the attractiveness of our model."

 

Tommy Kearns, CEO and founder of Xtremepush, added:

 

"We thank Duke Royalty for the capital support throughout a period of expansion in Xtremepush's business. Although the business has moved to another capital provider due to where the evolved business has reached in its growth lifecycle, we are grateful for the level of support and capital that we received since we partnered in early 2018. The flexibility of the solution and the ability for us to choose the timing of our refinancing event, certainly helped us focus on the execution of our global expansion plan."

 

***ENDS***

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon-Brookes / Hugo Evans

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Broker)

 

Julian Morse / Michael Johnson / Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

Newgate Communications

(PR)

 

Elisabeth Cowell / Ian Silvera / Megan Kovach

+44 (0) 20 3757 6880

Dukeroyalty@newgatecomms.com

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUQGBUPUGCP
Date   Source Headline
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update
21st Jun 20227:00 amRNSInterim Dividend and Dividend Declaration
1st Jun 20224:25 pmRNSHolding(s) in Company
27th May 20229:08 amRNSDirector / PCA Dealings
26th May 20223:23 pmRNSResult of General Meeting and Issue of Equity
11th May 20227:05 amRNSRaises £20m through Placing and PrimaryBid Offer
10th May 20225:08 pmRNSPrimaryBid Offer
10th May 20224:44 pmRNSPlacing to raise a minimum of £15 million
28th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
20th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
11th Apr 20227:00 amRNSTrading Update
18th Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Mar 20227:00 amRNSIncreased Interim Dividend & Dividend Declaration
2nd Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
25th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Feb 20227:00 amRNSFurther re: Directorate Change
14th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
2nd Feb 20227:00 amRNSDirectorate Changes
1st Feb 202210:02 amRNSReplacement - Trading Update
1st Feb 20227:00 amRNSTrading Update
20th Jan 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
23rd Dec 20212:30 pmRNSHolding(s) in Company
23rd Dec 20217:01 amRNSTrading Update
23rd Dec 20217:00 amRNSFollow-on investment into existing Royalty Partner
22nd Dec 20213:52 pmRNSFollow-on investment into existing Royalty Partner
16th Dec 20217:00 amRNSNew Royalty Agreement
14th Dec 20217:00 amRNSIncreased Interim Dividend & Dividend Declaration
7th Dec 20217:00 amRNSEnters into Largest Royalty Agreement To Date
3rd Dec 20217:00 amRNSInterim Results
2nd Dec 20217:00 amRNSCompletion of £4.2 million Follow-On Investment
25th Nov 20217:00 amRNSNotice of Interim Results
29th Oct 20214:03 pmRNSLong Term Incentive Plan Awards
27th Oct 20217:01 amRNSFollow-On Investment into Existing Royalty Partner
27th Oct 20217:00 amRNSHolding(s) in Company
22nd Oct 20214:36 pmRNSResult of Annual General Meeting
16th Sep 20217:01 amRNSInterim Dividend and Dividend Declaration
16th Sep 20217:00 amRNSFinal Results
7th Sep 20217:00 amRNS£2.2m Follow-On Investment into Royalty Partner
2nd Sep 20217:00 amRNSHolding(s) in Company
17th Aug 20217:00 amRNSInvestor Presentation
11th Aug 20217:00 amRNSSuccessful Exit of Investment in Royalty Partner
10th Aug 20217:00 amRNSNotice of Results and Analyst Presentation
2nd Aug 20217:00 amRNSNew Royalty Agreement
26th Jul 20217:00 amRNSTrading Update
22nd Jul 20217:00 amRNSNew Royalty Agreement
1st Jul 20217:00 amRNSNew Royalty Agreement with Fairmed Healthcare AG
17th Jun 20217:00 amRNSInterim Dividend and Dividend Declaration
10th May 20217:00 amRNSTrading Update
20th Apr 20215:22 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.